IP Library Granted Patent US 9,241,915
Granted Patent B2
US 9,241,915 · App. 14/310,822 · Granted Jan 26, 2016

Method for enhancing the bioavailability of ospemifene

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,241,915
App. No.
14/310,822
Granted
Jan 26, 2016
Kind
B2
Abstract

This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.

Claims (10)

1. A method for enhancing the bioavailability of a therapeutically active compound of the formula (I)

or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to an individual in connection with the intake of food.

2. The method according to claim 1 wherein compound (I) is ospemifene.

3. The method according to claim 1 wherein the compound is administered at a time point which is in the range defined by 1 hour before starting the food intake and 2 hours after starting the food intake.

4. The method according to claim 3 wherein the compound is administered at a time point which is in the range defined to begin at a time point during the food intake and to end 1 hour after the food intake was started.

5. The method according to claim 4 wherein the compound is administered at a time point which is no later than 0.5 hour after starting the food intake.

6. The method according to claim 1 wherein the food is any foodstuff of nutritional value being capable of causing secretion of bile acids.

7. The method according to claim 1 wherein the compound is used for treatment of osteoporosis.

8. The method according to claim 1 wherein the compound is used for treatment of symptoms related to skin atrophy, or to epithelial or mucosal atrophy.

9. The method according to claim 8 wherein the symptoms are urinary symptoms or vaginal symptoms.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2018
From: HORMOS MEDICAL OY
To: QUATRX PHARMACEUTICALS COMPANY
Reel/Frame 046240/0156 →
MOVABLE HYPOTHEC Recorded Apr 12, 2017
From: SHIONOGI INC.
To: DUCHESNAY INC.
Reel/Frame 042233/0807 →
CHANGE OF NAME Recorded Sep 21, 2016
From: HORMOS MEDICAL CORPORATION
To: HORMOS MEDICAL LTD.
Reel/Frame 040095/0849 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2016
From: ANTTILA, MARKKU
To: HORMOS MEDICAL CORPORATION
Reel/Frame 039805/0001 →